Biologic therapies in primary Sjögren's syndrome
1Rheumatology Department, University Hospital Birmingham (Selly Oak), Birmingham B29 6JD, UK. simon.bowman@uhb.nhs.uk
Current Pharmaceutical Biotechnology
|January 3, 2012
Summary
Primary Sjögren
Area of Science:
- Rheumatology and Immunology
Background:
- Primary Sjögren's Syndrome (PSS) is an autoimmune condition causing glandular dryness, fatigue, and reduced quality of life, primarily affecting women.
- Current treatments for PSS are mainly symptomatic, with limited options for managing systemic complications.
- Biologic therapies offer a targeted approach to autoimmune disease, potentially improving PSS treatment outcomes.
Purpose of the Study:
- To review the efficacy and challenges of biologic therapies in treating Primary Sjögren's Syndrome.
- To evaluate the current data on rituximab, an anti-B-cell therapy, for PSS.
- To explore the potential of other emerging biologic agents in PSS management.
Main Methods:
- Review of existing literature and clinical trial data on biologic therapies for PSS.
- Focus on rituximab, including its mechanism of action and clinical study status.
- Discussion of other biologic agents in development or clinical trials for autoimmune conditions.
Main Results:
- Rituximab has shown promise, with ongoing clinical trials investigating its utility in PSS.
- Biologic therapies represent a potentially more effective treatment strategy compared to conventional therapies.
- Challenges in biologic therapy use for PSS include patient selection and monitoring.
Conclusions:
- Biologic therapies, particularly rituximab, hold significant potential for treating Primary Sjögren's Syndrome.
- Further research and clinical trials are essential to establish the role of biologics in PSS management.
- Targeted biologic interventions may offer improved outcomes for patients with PSS and its extraglandular manifestations.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...